Alex De Caluwe
@AlexDeCaluwe
Followers
134
Following
261
Media
5
Statuses
99
Radiation Oncologist with a passion for novel immuno-RT combinations⚡#SBRT #Immunoradiation
Joined May 2016
RT @RO_GreenJournal: 🔬 The Neo-CheckRay trial explored pre-op immune-modulating SBRT (8 Gy x 3) + immunotherapy in luminal B breast cancer,….
thegreenjournal.com
Immune checkpoint inhibitors (ICI) have been investigated in combination with preoperative chemotherapy in early-stage triple negative breast cancer (TNBC) and in estrogen receptor-positive, human...
0
12
0
RT @aftimosp: Investigator-initiated study sponsored by @JulesBordet and chaired by @AlexDeCaluwe and Laurence Buisseret. Primary endpoint….
0
3
0
RT @VJOncology: October is #BreastCancerAwarenessMonth 📣 . Check out this interview from #ESMO2024 w/ @AlexDeCaluwe | Neo-CheckRay: #chemot….
vjoncology.com
Alex De Caluwe, MD, Jules Bordet Institute, Brussels, Belgium, gives an overview of the Phase II Neo-CheckRay trial (NCT03875573), which assessed chemotherapy with stereotactic body radiation therapy...
0
1
0
RT @JDekervel: 👏Fascinating results on RT + IO in breast cancer presented by my good friend @AlexDeCaluwe at this year's #ESMO2024 - makes….
0
1
0
RT @Mat_Guc: Randomized phase 2 trial evaluating SBRT to the Primary Breast Cancer +/- Durvalumab +/- Oleclumab combined with Neoadjuvant C….
0
25
0
RT @ElisaAgostinett: At #ESMO24 @AlexDeCaluwe presents results of NeoCheckRay, evaluating SBRT⚡️+/- durva +/- oleclumab combined with NACT….
0
13
0
RT @E_de_Azambuja: NEOCheck-Ray: does adding #durvalumab and SBRT to neoadjuvant chemotherapy improves pCR in Lum B #ebc ? @AlexDeCaluwe @J….
0
24
0
RT @Lucarecco: #ESMO24 proffered eBC session. Neo-CheckRay trial presented by @AlexDeCaluwe demonstrated numerically ⬆️ RCB0/1 with Durvalu….
0
11
0
RT @GuiNaderMarta: Very interesting results by PD-L1 status. Unlike Keynote756 and Checkmate7FL, which showed higher benefit of IO in PD-L1….
0
6
0
RT @GuiNaderMarta: Neo-CheckRay presented by @AlexDeCaluwe . Ph2 II trial in early LumB BC, exploring NACT + SBRT + IO (anti-PD-L1, anti-CD….
0
15
0
RT @Icro_Meattini: Congratulations @AlexDeCaluwe and Bordet team for this timely study focus on crucial topic RT-drug synergy. Primary endp….
0
16
0
RT @Lucarecco: ⏳Can’t wait for the eBC proffered session about to start at 10:15 in #ESMO24 Barcelona Auditorium! . @AlexDeCaluwe from @Jul….
0
8
0
RT @AnoukGoudsmit: The beautiful @JulesBordet family is reunited in Barcelona for the European Society of Medical Oncology annual meeting….
0
7
0
RT @SuyogCancer: The trial for small cell lung cancer .Adriatic .Durvalumab consolidation post CTRT for Limited stage SCLC. HR PFS -16.6….
0
27
0
RT @NiuSanford: Where is RT 👀?. Despite overall dearth of RCTs comparing local modalities in HCC, we have randomized studies in support of….
0
37
0
RT @weoncologists: Durvalumab becomes the 1st and only immunotherapy to significantly enhance OS and PFS in limited-stage small cell #LungC….
0
10
0
RT @Sushilberiwal: Largest study for 1-2 macromets in both mastectomy and BCS showing no difference in DFS and axillary recurrence with A….
nejm.org
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limit...
0
23
0
RT @sbrtmemes: Time to rebrand radiotherapy as radiatumumab and re publish all our OS, PFS, and safety profile data .@US_FDA .@POTUS .#rado….
0
20
0
RT @ESTRO_RT: 🌟Spotlight on #Immunotherapy: Discover the visionary insights of Eric Deutsch and Udo Gaipl, course directors of our upcoming….
0
12
0
RT @drenriquegrande: ⚡️ Immunotherapy transformed cancer care, but not all respond. This review examines current successes, challenges, and….
0
27
0